Executives of Optimer Pharmaceuticals Inc. didn't have to wait until after the long weekend for an FDA decision on the company's macrolide antibiotic Dificid (fidaxomicin). Though the PDUFA date was set for May 30, the agency approved the drug Friday afternoon for treating Clostridium difficile-associated diarrhea (CDAD), a common hospital-acquired infection.